IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein

September 2, 2025/in Clinical Trial, Metastatic, Phase 1/by Max

On August 29, 2025, a clinical trial plan (Investigational New Drug application) was submitted to the Ministry of Food and Drug Safety (MFDS) of South Korea to initiate phase 1 clinical trials for ITC-6146RO. ITC-6146RO is an antibody-drug conjugate (ADC) designed to target solid tumors overexpressing the B7-H3 protein, such as metastatic castration-resistant prostate cancer […]